Relapsed Or Refractory Follicular Lymphoma clinical trials

Explore recruiting relapsed or refractory follicular lymphoma clinical trials.

Recruiting relapsed or refractory follicular lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Follicular Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma

Slovakia, Poland, Spain, Hungary, Romania, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Denmark, Hungary, Slovakia, Sweden, Austria, Greece +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Or Refractory Follicular Lymphoma trials by city

Relapsed Or Refractory Follicular Lymphoma clinical trials

Recruiting relapsed or refractory follicular lymphoma studies right now

CAR-T Followed by Bispecific Antibodies

huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Also recruiting in Europe

A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Relapsed Or Refractory Follicular Lymphoma trials by city

Other conditions